Mean direct medical care costs associated with cervical cancer for commercially insured patients in Texas

Lairson, David R.; Fu, Shuangshuang; Chan, Wenyaw; Xu, Li; Shelal, Zeena; Ramondetta, Lois M.

doi:10.1016/j.ygyno.2017.02.011

Cited by 27 publications

(22 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lairson et al analyzed commercially insured cervical cancer patients in Texas and observed first-year medical costs of $60,828 for cervical cancer cases and $9,982 for controls. 3 United States health plan. 4 They found cumulative 4-year health care costs of $29,649 after adjusting for mortality.…”

Section: Discussionmentioning

confidence: 99%

“…4 They found cumulative 4-year health care costs of $29,649 after adjusting for mortality. However, these studies have limitations in external validity/generalizability as the study populations were limited to the adult cancer survivors in Texas, 2,3 and/or the cancer survivors in private insurance settings only. 3,4 Although, more generalizable, the cost estimates for cervical cancer from our analysis are lower than those from previous literature.…”

Section: Discussionmentioning

confidence: 99%

“…However, these studies have limitations in external validity/generalizability as the study populations were limited to the adult cancer survivors in Texas, 2,3 and/or the cancer survivors in private insurance settings only. 3,4 Although, more generalizable, the cost estimates for cervical cancer from our analysis are lower than those from previous literature. This is because the estimates reported herein are the annual estimates of prevalent cases of cervical cancer.…”

Section: Discussionmentioning

confidence: 99%

“…2 In a commercially insured population in Texas between 2001 and 2014, health care costs in the first and second years after diagnosis were $50,846 and $27,656 higher, respectively, in cervical cancer cases compared to controls. 3 National estimates of cervical cancer costs were last published in 2008 (reported in 2003 US dollars), at which time mortality adjusted 4-year health care costs were $29,649. 4 Recent country-level estimates of economic burden are lacking.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Economic and Humanistic Burden of Cervical Cancer in the United States: Results from a Nationally Representative Survey

Shah

Nwankwo

Kwon

et al. 2020

Journal of Women's Health

View full text Add to dashboard Cite

Objective: To measure the economic and humanistic burden of cervical cancer in the United States. Materials and Methods: This was a retrospective analysis of Medical Expenditure Panel Survey data (2006-2015). Cervical cancer cases were identified using International Classification of Diseases, Ninth Revision, Clinical Modification code ''180'' or clinical classification software code ''26''. The control group included women without any cancer diagnosis. Study outcomes included health care resource use (institutional inpatient and outpatient, emergency room, and physician office visits), costs, limitations in activities of daily living, and quality of life (general health status, 12-Item Short Form Health Survey [SF-12] physical and mental component summary [MCS], EuroQol-5D and Short-Form Six-Dimension health utility, and Patient Health Questionnaire-2 depression severity). Generalized linear models, controlling for sociodemographic and clinical covariates, were conducted to compare outcomes between cases and controls. Results: The analytic cohort included 275,246 cervical cancer cases and 146,061,609 noncancer controls. Cases were significantly older (mean age [years]: 42.03 vs. 36.98) and had a higher Charlson comorbidity burden (mean score: 1.06 vs. 0.46) versus controls. Multivariate analyses suggested that compared to controls, cancer cases had significantly higher costs: institutional outpatient

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Economic and Humanistic Burden of Cervical Cancer in the United States: Results from a Nationally Representative Survey

Shah

Nwankwo

Kwon

et al. 2020

Journal of Women's Health

View full text Add to dashboard Cite

show abstract

“…Implementation of this wide range of services capitalizes on the identification and proper allocation of previously existing resources, and thus as an intervention, the cost of the intervention is derived primarily from the salary and training of the navigation staff. Considering the salary of a lay navigator compared with the cost of cervical cancer treatment, which is approximately $45,000 to $50,000 per patient for the first year of treatment, this intervention is feasible and well worth the additional costs 32,33 . Formalized cost modeling is needed to further assess the cost‐effectiveness of this intervention in this patient population.…”

Section: Discussionmentioning

confidence: 99%

Socially determined cervical cancer care navigation: An effective step toward health care equity and care optimization

Dessources

Hari

Pineda

et al. 2020

Cancer

View full text Add to dashboard Cite

Background Despite being the standard of care for patients with locoregional cervical cancer, many patients do not complete all components of primary chemoradiotherapy (pCRT): external beam radiotherapy, chemosensitization, and brachytherapy. Incomplete or protracted pCRT is associated with worse survival. The authors implemented a socially determined cervical cancer care navigation program at a public safety‐net hospital to improve treatment adherence. Methods Patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB1 to IVA cervical cancer who underwent pCRT from 2012 to 2016 were prospectively enrolled into this navigation program spanning the medical, financial, and psychosocial aspects of care. This patient cohort was compared with a similar cohort of consecutive nonnavigated patients who were treated from 1998 to 2008. Patient characteristics, treatment data, and patient outcomes were collected. A database of navigation encounters was maintained prospectively. Results A total of 46 patients composed the navigated cohort and 85 patients composed the nonnavigated cohort. After implementation of the cervical cancer care navigation program, the percentage of patients receiving ≥5 cycles of weekly cisplatin increased from 74% to 93% (P < .01) and rates of the initiation of brachytherapy during external beam radiotherapy increased from 49% to 78% (P < .01). The median treatment time was reduced from 67 days in the nonnavigated patients to 55 days in the navigated patients (P < .01). Approximately 95% of navigated patients who completed pCRT did so within 63 days, compared with 52% of nonnavigated patients (P < .01). Treatment completion within 63 days was associated with significantly improved overall survival. Conclusions Socially informed cervical cancer care navigation can significantly improve the timeliness of guideline‐based care, enhance access to resources for underserved minority patients receiving pCRT, and may improve overall patient outcomes.

show abstract

Costs of cancer along the care continuum: What we can expect based on recent literature

Pisu

Henrikson

Banegas

et al. 2018

Cancer

View full text Add to dashboard Cite

Background Cancer costs should be discussed by patients and providers, but information is not readily available. Results from recently published studies (in the last 5 years) on direct and indirect cancer costs may help guide these discussions. Methods The authors reviewed studies published between 2013 and 2017 that reported direct health care costs and indirect (productivity losses) costs. The annual mean total and net costs of cancer were summarized for all payers and for survivors only by age (ages 18‐64 and ≥65 years), by phase of care (initial [ie, 12 months from diagnosis], continuing, and end‐of‐life [ie, 12 months before death]), or for recently diagnosed (within 1‐2 years of diagnosis) and longer term survivors. Results For all payers combined, costs for cancers like breast, prostate, colorectal, and lung cancers were $20,000 to $100,000 in the initial phase, $1000 to $30,000 annually in the continuing phase, and ≥$60,000 in the end‐of‐life phase. Annual out‐of‐pocket costs to recently diagnosed survivors were >$1000 for medical care and time costs, approximately $2000 for productivity losses, and from $2500 to >$4000 for employment disability, depending on age. For longer term survivors, the cost of medical care was approximately $1500 for older survivors and $747 for younger survivors, time costs were $831 to $955 for older survivors and $459 to $630 for younger survivors, and productivity losses were approximately $800. Disability among long‐term survivors was similar to that among short‐term survivors. Limitations of the reviewed studies included older data and under‐representation of higher cost cancers. Conclusions Frequently updated cost information for all cancer types is needed to guide discussions of anticipated short‐term and long‐term cancer‐related costs with survivors. Cancer 2018;000:000‐000. © 2018 American Cancer Society.

show abstract

Mean direct medical care costs associated with cervical cancer for commercially insured patients in Texas

Cited by 27 publications

References 19 publications

Economic and Humanistic Burden of Cervical Cancer in the United States: Results from a Nationally Representative Survey

Economic and Humanistic Burden of Cervical Cancer in the United States: Results from a Nationally Representative Survey

Socially determined cervical cancer care navigation: An effective step toward health care equity and care optimization

Costs of cancer along the care continuum: What we can expect based on recent literature

Contact Info

Product

Resources

About